Takeda, Roivant create new home for relugolix
Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) and Roivant Sciences Ltd. (Hamilton, Bermuda) launched Myovant Sciences Ltd., a newco which will hold exclusive ex-Asia rights to women's health and prostate cancer candidate relugolix ( TAK-385). The companies did not disclose financial terms of their deal.
Chief Medical and Scientific Officer Andrew Plump had said during Takeda's FY15 earnings call in May that the company was seeking a partner to develop relugolix outside of Japan. Takeda will retain rights to relugolix in Japan, where it is running two Phase III trials of the candidate to treat uterine fibroids. The luteinizing hormone-releasing hormone ( LHRH) receptor antagonist also is in development to treat prostate cancer and endometriosis. ...